Elsevier

Biochimie

Volume 80, Issue 3, March 1998, Pages 255-270
Biochimie

Diversity of DNA topoisomerases I and inhibitors

https://doi.org/10.1016/S0300-9084(98)80008-4Get rights and content

Abstract

The present review first describes the different type I topoisomerases found in eukaryotic cells: nuclear topoisomerase I (top1), topoisomerase 3 (top3), mitochondrial topoisomerase I and viral topoisomerases I. The second part of the review provides extensive information on the topoisomerase I inhibitors identified to date. These drugs can be grouped in two categories: top1 poisons and top1 suppressors. Both inhibit enzyme catalytic activity but top1 poisons trap the top1 catalytic intermediates (‘cleavage complexes’) while top1 suppressors prevent or reverse top1 cleavage complexes. The molecular interactions of camptothecin with the top1 cleavage complexes are discussed as well as the mechanisms of selective killing of cancer cells.

References (200)

  • M.F. Christman et al.

    Mitotic recombination in the rDNA of S cerevisiae is suppressed by the combined action of DNA topoisomerase I and II

    Cell

    (1988)
  • R.A. Kim et al.

    A subthreshold level of DNA topoisomerase leads to the excision of yeast rDNA as extrachromosomal rings

    Cell

    (1989)
  • A.M. Knab et al.

    Mechanisms of camptothecin resistance in Yeast DNA topoisomerase I mutants

    J Biol Chem

    (1993)
  • C. Upton et al.

    Identification and DNA sequence of the Shope fibroma virus DNA topoisomerase I gene

    Virology

    (1990)
  • S. Shuman

    Site-specific DNA cleavage by Vaccinia virus DNA topoisomerase I. Role of nucleotide sequence and DNA secondary structure

    J Biol Chem

    (1991)
  • N. Palaniyar et al.

    SFV topoisomerase: sequence specificity in a genetically mapped interval

    Virology

    (1996)
  • L. Stewart et al.

    Reconstitution of human topoisomerase I by fragment complementation

    J Mol Biol

    (1997)
  • L. Stewart et al.

    The domain organization of human topoisomerase I

    J Biol Chem

    (1996)
  • L. Stewart et al.

    Biochemical and Biophysical analyses of recombinant forms of human topoisomerase I

    J Biol Chem

    (1996)
  • Y. Pommier et al.

    Phosphorylation of mammalian DNA topoisomerase I and activation by protein C

    J Biol Chem

    (1990)
  • J.P. Armand et al.

    CPT-11 (irinoteccan) in the treatment of colorectal cancer

    Eur J Cancer

    (1995)
  • S. O'Reilly et al.

    The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996

    Crit Rev Oncol/Hematol

    (1996)
  • Y.H. Hsiang et al.

    Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I

    J Biol Chem

    (1985)
  • C. Jaxel et al.

    Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin

    J Biol Chem

    (1991)
  • B.J. Bonven et al.

    A high affinity topoisomerase I binding sequence is clustered at DNAase I hypersensitive sites in Tetrahymena R-chromatin

    Cell

    (1985)
  • A.F. Stewart et al.

    Camptothecin-induced in vivo topoisomerase I cleavages in the transcriptionally active tyrosine aminotransferase gene

    Cell

    (1987)
  • J.C. Wang

    DNA topoisomerases

    Annu Rev Biochem

    (1996)
  • J.C. Wang

    DNA topoisomerases

    Annu Rev Biochem

    (1985)
  • M. Gellert

    DNA topoisomerases

    Annu Rev Biochem

    (1981)
  • L.F. Liu

    DNA topoisomerase poisons as antitumor drugs

    Annu Rev Biochem

    (1989)
  • Y. Pommier et al.

    Mammalian DNA topoisomerase I and its inhibitors

  • W. Wallis et al.

    A hyper-recombination mutation in S cerevisiae identifies a novel eukaryotic cell phase

    Cell

    (1989)
  • K.C. Hanai et al.

    Human TOP3: a single copy gene encoding DNA topoisomerase III

  • E. Fritz et al.

    Overexpression of a truncated human topoisomerase III partially corrects multiple aspects of the ataxia-telangiectesia phenotype

  • S. Gangloff et al.

    The yeast type 1 topoisomerase top3 interacts with sgsl, a DNA helicase homolog: a potential eukaryotic reverse gyrase

    Mol Cell Biol

    (1994)
  • D.E. Pulleyblank et al.

    Partial purification of protein from calf thymus

    Biochemistry

    (1975)
  • L.F. Liu

    HeLa toposiomerase I

    Methods enzymol

    (1983)
  • G. Brun et al.

    DNA topoisomerase I from mitochondria of Xenopus laevis oocytes

    Eur J Biochem

    (1981)
  • F.J. Castora et al.

    ATP inhibits nuclear and mitochondrial type I topoisomerases from human leukemia cells

  • G.M. Lazarus et al.

    Purification and characterization of a type I DNA topoisomerase from calf thymus mitochondria

    Biochemistry

    (1987)
  • M.P. Lee et al.

    DNA topoisomerase I is essential in Drosophila melanogaster

  • S. Morham et al.

    Targeted disruption of the mouse topoisomerase I gene by camptothecin selection

    Mol Cell Biol

    (1996)
  • M-E. Fernandez-Beros et al.

    Conditional growth of Escherichia coli caused by expression of vaccinia virus DNA topoisomerase I

    J Bacteriol

    (1992)
  • M-A. Bjornsti et al.

    Expression of human DNA topoisomerase I in Yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin

    Cancer Res

    (1989)
  • K.R. Madden et al.

    Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin

    Cancer Res

    (1992)
  • M.M. Heck et al.

    Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle

  • T. Uemura et al.

    Isolation of type I and II DNA topoisomerase mutants from fission yeast: Single and double mutants show different phenotypes in cell growth and chromatin organization

    EMBO J

    (1984)
  • J.L. Nitiss et al.

    Using yeast to understand drugs that target topoisomerases

    Ann NY Acad Sci

    (1996)
  • G.H. Goldman et al.

    Differential poisoning of human and Aspergillus nidulans DNA topoisomerase 1 by bi- and terbenzimidazoles

    Biochemistry

    (1997)
  • W.R. Batter et al.

    A DNA nicking-closing enzyme encapsidated in vaccinia virus: partial purification and properties

  • Cited by (125)

    • 3EZ, 20Ac-ingenol induces cell-specific apoptosis in cyclin D1 over-expression through the activation of ATR and downregulation of p-Akt

      2018, Leukemia Research
      Citation Excerpt :

      The majority of anticancer drugs target the DNA in tumor cells, inducing various types of DNA damage. The most effective anticancer drugs are DNA topo I or II inhibitors, which stabilize otherwise transient DNA and topo I or topo II associations that form “cleavable complexes” which are then converted into DNA double-strand breaks (DSBs) [2–7]. The induction of DNA damage as well as DSBs triggers a complex formation of essential factors and highly coordinated series of events known as the DNA damage response (DDR) [8,9].

    • Cytogenetic evidence that DNA topoisomerase II is not involved in radiation induced chromsome-type aberrations

      2015, Mutation Research - Genetic Toxicology and Environmental Mutagenesis
    • Biological potential of carbazole derivatives

      2015, European Journal of Medicinal Chemistry
      Citation Excerpt :

      G-quadruplexes are formed by association of two or four separate strands of DNA (intermolecular quadruplex) (Fig. 31b) or by rolling up a single strand (intramolecular quadruplex) with parallel or antiparallel orientation [92,94–96,139]. It is believed that the therapeutic effectiveness of such ligands in treatment of neoplasmic diseases is attributed to inhibition or poisoning of some DNA enzymes, in particular topoizomerases and telomerase [92,94,96,139–145]. Topoizomerases are the enzymes which in vivo unfold the double DNA helix to make the matrix accessible to replication or transcription enzymes.

    View all citing articles on Scopus
    View full text